66183-71-9

Basic information

• Product Name: ethyl 5-oxo-DL-prolinate
• Synonyms: ethyl 5-oxo-DL-prolinate;(±)-5-Oxoproline ethyl;5-Oxo-DL-Proline ethyl;ethyl 5-oxopyrrolidine-2-carboxylate;Ethyl DL-pyroglutaMate
• CAS NO: 66183-71-9
• Molecular Formula: C₇H₁₁NO₃
• Molecular Weight: 157.16714
• EINECS: 266-226-9
• Mol File: 66183-71-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 54 °C
• Boiling Point: 312.7°Cat760mmHg
• Flash Point: 142.9°C
• Appearance: /
• Density: 1.161g/cm³
• Vapor Pressure: 0.000519mmHg at 25°C
• Refractive Index: 1.466
• PKA: 14.78±0.40(Predicted)
• CAS DataBase Reference: ethyl 5-oxo-DL-prolinate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-oxo-DL-prolinate(66183-71-9)
• EPA Substance Registry System: ethyl 5-oxo-DL-prolinate(66183-71-9)

Safety Data

• Hazardous Substances Data: 66183-71-9(Hazardous Substances Data)

Usage

Description

Ethyl 5-oxo-DL-prolinate, also known as 5-Ethylcarboxyl-2-pyrrolidinone, is an organic compound commonly utilized in the synthesis of various chemical products. It is characterized by its unique chemical structure, which allows it to participate in a range of reactions and contribute to the formation of different compounds.

Uses

Used in Chemical Synthesis:
Ethyl 5-oxo-DL-prolinate is used as a reactant for the preparation of N-halo compounds. This application is particularly relevant in the chemical industry, where N-halo compounds are essential intermediates in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals.
The reason for using ethyl 5-oxo-DL-prolinate in this context is its ability to react with primary and secondary amines or amides in the presence of sodium hypohalite. This reaction leads to the formation of N-halo compounds, which are valuable building blocks for further chemical transformations and the development of new products.

InChI:InChI=1/C7H11NO3/c1-2-11-7(10)5-3-4-6(9)8-5/h5H,2-4H2,1H3,(H,8,9)/t5-/m0/s1

Upstream product

• 55895-85-7 diethyl 2-aminopentanedioate 
• 50-00-0 formaldehyd 
• 64-17-5 ethanol 
• 149-87-1 Pyroglutamic acid 
• 75-03-6 ethyl iodide 
• 617-65-2 Glutamic acid 
• 251924-83-1 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate 

Downstream Products

• 84911-17-1 Ethyl 5-Thioxopyrrolidine-2-carboxylate 
• 94135-34-9 pyroglutamic hydrazide 
• 609-36-9 rac-Pro-OH 
• 868066-41-5 ethyl 4-allyl-2,7-dioxo-1-phenyl-1,3-diazepane-4-carboxylate 
• 868066-43-7 ethyl 4-allyl-2,7-dioxo-1-benzyl-1,3-diazepane-4-carboxylate 
• 868066-23-3 ethyl 3,4-diallyl-2,7-dioxo-1-phenyl-1,3-diazepane-4-carboxylate 
• 868066-27-7 ethyl 4-allyl-3-(2-methylprop-2-enyl)-1-phenyl-2,7-dioxo-1,3-diazepane-4-carboxylate 
• 868066-25-5 ethyl 4-allyl-1-benzyl-3-(2-chloroprop-2-enyl)-2,7-dioxo-1,3-diazepane-4-carboxylate 
• 868066-29-9 ethyl 4-allyl-1-benzyl-3-(2-chloroprop-2-enyl)-2,7-dioxo-1,3-diazepane-4-carboxylate 
• 868066-31-3 ethyl 4-allyl-1-benzyl-3-[2-(ethoxycarbonyl)prop-2-enyl]-2,7-dioxo-1,3-diazepane-4-carboxylate 

Relevant articles and documents

-

-

CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or -CR0--, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is -CRe --, or, -N--, where Re is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1- C6 linear or branched chain alkyl, etc.; Q is --CO--, --(CH2)q--, --(CHRs)q--, or -(CRsRt)q- -, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to compbinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A-a, or a salt thereof: Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.